1.Isolation and Characteristic of an Azo Dye-decolorizing Salt-tolerant Bacteria Strain GYW
Jianbo GUO ; Lihui ZHANG ; Jingliang YANG ; Yubin HONG ; Chun LIU ; Zaixing LI ; Xiaolei WANG ; Li KANG
Microbiology 1992;0(05):-
A salt-tolerant strain GYW capable of decolorating azo dye was isolated and identified as Halo-monas sp.by 16S rDNA.The result showed that the decolorizing salt-tolerant bacteria could survive above the 10% salt concentration and it could decolorize many dyes.The strain had a high decolorizing rate on acid red GR under the condition of pH 7.5,anaerobic 30?C and 10% NaCl.The ion of Cl- strong inhibited the decolorization of acid red GR,and the ion of SO42- affected little on the decolorization,and the lycine addi-tion with the optimal concentration of 200 mg/L could enhanced the decolorization rate under high NaCl concentration.
2.Correlation between gastrointestinal dysfunction and both severity and prognosis in patients suffering from heatstroke
Lihui MIAO ; Qing SONG ; Hui LIU ; Feihu ZHOU ; Hongjun KANG ; Liang PAN ; Jie HU ; Jiekun CHEN ; Ting ZHANG ; Zhenhua WU ; Jiajia ZHAO ; Jingjiang ZHOU
Chinese Critical Care Medicine 2015;(8):635-638
ObjectiveTo investigate the relationship between gastrointestinal dysfunction and both severity and prognosis in patients with heatstroke (HS).Methods A retrospective analysis was conducted. Clinical data from 39 patients with HS seeking for treatment in Department of Critical Care Medicine of Chinese PLA General Hospital from January 2013 to September 2014 were enrolled. The patients were divided into two groups: gastrointestinal dysfunction group and non-gastrointestinal dysfunction group. The acute physiology and chronic health evaluationⅡ(APACHEⅡ) score within 24 hours of admission and 28-day mortality were compared between two groups. In gastrointestinal dysfunction group, the gastrointestinal dysfunction score, the duration days of gastrointestinal dysfunction, the length of intensive care unit (ICU) stay, and the duration of mechanical ventilation were collected. Pearson correlation analysis was used to analyze the relationship between gastrointestinal function and the severity of the ailment as well as the prognosis.Results Among 39 patients with HS, 32 of them showed gastrointestinal dysfunction with an incidence of 82.05%. In gastrointestinal dysfunction group, the gastrointestinal dysfunction score was 2.3±0.8, the duration of gastrointestinal dysfunction was (17.3±15.2) days, the length of ICU stay was (37.8±25.0) days, and the duration of mechanical ventilation was (27.8±14.0) days. APACHEⅡ score in gastrointestinal dysfunction group was significantly higher than that of the non-gastrointestinal dysfunction group (26.30±6.00 vs. 17.40±6.00, t = 3.555,P = 0.001). The 28-day mortality in gastrointestinal dysfunction group was slightly higher than that of the non-gastrointestinal dysfunction group without statistically significant difference [43.75% (14/32) vs. 14.29% (1/7),P = 0.216]. It was shown by Pearson analysis that gastrointestinal dysfunction score was positively correlated with APACHEⅡ score (r = 0.727,P = 0.000), and the duration of gastrointestinal dysfunction was positively correlated with the length of ICU stay (r = 0.797,P = 0.000) and the duration of mechanical ventilation (r = 0.634,P = 0.000). Conclusion The results suggest that gastrointestinal function in patients with HS reflects the severity and prognosis of the ailment.
3.Audiological Characteristics in 832 Deaf Children with Biallelic Causative Mutations in GJB2,SLC26A4 Gene
Qingjia CUI ; Guojian WANG ; Yuan ZHANG ; Ying YANG ; Dongyang KANG ; Yanshun DU ; Liping ZHAO ; Shasha HUANG ; Wei ZHANG ; Xibin SUN ; Pu DAI ; Lihui HUANG
Journal of Audiology and Speech Pathology 2014;(2):120-123
Objective To determine the audiological characteristics in 832 deaf children with biallelic causative mutations in GJB2 ,SLC26A4 gene .Methods The 832 patients received deafness gene screening ,553 were GJB2 gene biallelic causative mutations ,279 were SLC26A4 gene biallelic causative mutations .Patients were divided into four groups according to ages of hearing loss onset :<1 ,1~3 ,3~6 ,6~12 years old ,and the audiological character-istics and prevalence of GJB2 ,SLC26A4 gene mutations at different ages of onset .Results The prevalence of GJB2 gene mutations at four groups was 37 .97% (210/553) ,38 .34% (212/553) ,16 .27% (90/553) ,7 .41% (41/553) ,re-spectively ;the prevalence of SLC26A4 gene mutations at four groups was 25 .45% (71/279) ,44 .80% (125/279) , 20 .07% (56/279) ,9 .67% (27/279) ,respectively .The difference between GJB2 and SLC26A4 gene was significant(P=0 .001) .The prevalence of profound hearing loss with GJB2 gene mutations at four groups were 66 .67% (140/210) ,61 .32% (130/212) ,47 .78% (43/90) ,41 .46% (17/41) ,respectively .The difference was significant (P=0 .004) ,while the difference in 279 patients with SLC26A4 gene mutations was not statistically significant (P= 0 . 083) .Conclusion The age of hearing loss onset in patients with biallelic causative mutations in GJB 2 or SLC26A4 gene refers to 0~3 years -old ,hearing loss in patients with GJB2 ,SLC26A4 gene mutations gives priority to pro-found .The age of hearing loss onset is smaller ,the ratio of profound hearing loss is higher .Patients with severe and profound hearing impairment should be performed the genetic testing when the age of onset under 12 .
4.Research progress of metabolic associated fatty liver disease and chronic complications of diabetes mellitus
Jiachen LI ; Yaxing KANG ; Yangying JI ; Lihui ZHANG
Chinese Journal of Diabetes 2023;31(12):950-952
The incidence of metabolic associated fatty liver disease(MAFLD)and diabetes mellitus(DM)is gradually increasing in China.Both are metabolic diseases and influence each other.MAFLD increases the likelihood of chronic complications in patients with DM.This article reviews the research progress of MAFLD and chronic complications of DM.
5.Relationship between thyroid hormone resistance and hyperuricemia in population with normal thyroid function
Yuwen SUN ; Jing WANG ; Lihui KANG ; Lin KANG ; Ting LIU ; Lili LIANG ; Yonghong NIU
Chinese Journal of Health Management 2024;18(6):428-432
Objective:To investigate the correlation between thyroid hormone resistance and hyperuricemia in euthyroid population.Methods:It was a cross-sectional study. A total of 548 euthyroid subjects who were hospitalized or underwent physical examination in the Heart Center and Health Management Center of the First Affiliated Hospital of Tsinghua University from January 2021 to December 2022 were selected. Thyroid function, uric acid, blood lipid and other indicators were collected in the subjects, and thyroid function parameters were calculated: thyroid-stimulating hormone index (TSHI), thyrotropin T4 resistance index (TT4RI), parametric thyroid feedback quantile-based index (PTFQI), free triiodothyronine/free thyroxine (FT3/FT4), the sum activity of peripheral deiodinases (SPINA-GD) and the secretory capacity of the thyroid gland (SPINA-GT). According to uric acid level, the subjects were divided into high uric acid group and normal group, the clinical characteristics and thyroid function parameters of the two groups were compared, the correlation between thyroid hormone resistance and hyperuricemia was further explored.Results:Compared with the normal group, male proportion (94.4% and 52.5%), smoking rate (5.2% and 21.3%), body mass index [(27.10±3.96) and (24.26±3.42) kg/m 2], waist-to-hip ratio [0.90(0.86, 0.94) and 0.86(0.80, 0.91)], serum creatinine [(85.50±12.27) and (73.77±28.79) μmol/L], total cholesterol [(5.08±0.99) and (4.72±0.86) mmol/L], triglyceride [2.10(4.40, 5.59) and 1.14(0.79, 1.67)mmol/L], low-density lipoprotein [(3.19±0.97) and (2.85±0.84) mmol/L] and homocystine [(15.07±9.13) and (12.50±10.85) μmol/L] were all higher in the high uric acid group, and the level of high-density lipoprotein [1.15(1.43, 2.88) and 1.39(1.16, 1.64) mmol/L] was lower (all P<0.05). In the aspect of thyroid hormone and thyroid function parameters, the FT4[16.90(5.40,17.95) and 16.00(14.30,17.80) pmol/L], FT3[5.56(5.25, 5.94) and 5.22(4.81, 5.63) pmol/L], FT3/FT4 [0.34(0.31, 0.37) and 0.32(0.29, 0.36)], TSHI (2.70±0.50 and 2.58±0.60), PTFQI (0.406±0.332 and 0.335±0.353) and SPINA-GD [3.72(3.41, 4.05) and 3.52(3.18, 4.00) ]were all higher in high uric acid group than those in normal group(all P<0.05). Spearman correlation analysis showed that blood uric acid level was positively correlated with FT4 ( r=0.185), FT3 ( r=0.422), FT3/FT4 ( r=0.16), TSHI ( r=0.134), TT4RI ( r=0.09), PTFQI ( r=0.121) and SPINA-GD ( r=0.157) (all P<0.05). Conclusion:In people with euthyroid function, central resistance to thyroid hormone is correlated with hyperuricemia.
6.Drug Survival Rates of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis.
Ji Hyoun KANG ; Dong Jin PARK ; Jeong Won LEE ; Kyung Eun LEE ; Lihui WEN ; Tae Jong KIM ; Yong Wook PARK ; Shin Seok LEE
Journal of Korean Medical Science 2014;29(9):1205-1211
We investigated the compliance of Korean patients using tumor necrosis factor (TNF) inhibitors to treat rheumatoid arthritis (RA) and ankylosing spondylitis (AS), and identified potential predictors associated with treatment discontinuation. The study population comprised 114 RA and 310 AS patients treated with TNF inhibitors at a single tertiary center for at least 1 yr from December 2002 to November 2011. Of the 114 RA patients, 64 (56.1%) discontinued their first TNF inhibitors with a mean duration of 18.1 months. By contrast, 65 of 310 patients (21.0%) with AS discontinued their first TNF inhibitors, with a mean duration of 84 months. Although the survival rate did not differ among the three TNF inhibitors in the AS patients, the etanercept group had a lower discontinuation rate than the infliximab group in the RA patients. In addition, RA patients who received corticosteroids in combination with TNF inhibitors were more likely to discontinue their TNF inhibitors. The independent predictors of drug discontinuation in AS patients were male gender and complete ankylosis on radiographs of the sacroiliac joint. Our results provide further evidence that real-life treatment outcomes of RA and AS patients may be different from those observed in randomized clinical trials.
Adult
;
Aged
;
Antibodies, Monoclonal/therapeutic use
;
Antibodies, Monoclonal, Humanized/therapeutic use
;
Antirheumatic Agents/*therapeutic use
;
Arthritis, Rheumatoid/*drug therapy/mortality
;
Cohort Studies
;
Female
;
Follow-Up Studies
;
Humans
;
Immunoglobulin G/therapeutic use
;
Male
;
Middle Aged
;
Proportional Hazards Models
;
Receptors, Tumor Necrosis Factor/therapeutic use
;
Sex Factors
;
Spondylitis, Ankylosing/*drug therapy/mortality/radiography
;
Tertiary Care Centers
;
Treatment Refusal
;
Tumor Necrosis Factors/*antagonists & inhibitors/metabolism
7.Drug Survival Rates of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis.
Ji Hyoun KANG ; Dong Jin PARK ; Jeong Won LEE ; Kyung Eun LEE ; Lihui WEN ; Tae Jong KIM ; Yong Wook PARK ; Shin Seok LEE
Journal of Korean Medical Science 2014;29(9):1205-1211
We investigated the compliance of Korean patients using tumor necrosis factor (TNF) inhibitors to treat rheumatoid arthritis (RA) and ankylosing spondylitis (AS), and identified potential predictors associated with treatment discontinuation. The study population comprised 114 RA and 310 AS patients treated with TNF inhibitors at a single tertiary center for at least 1 yr from December 2002 to November 2011. Of the 114 RA patients, 64 (56.1%) discontinued their first TNF inhibitors with a mean duration of 18.1 months. By contrast, 65 of 310 patients (21.0%) with AS discontinued their first TNF inhibitors, with a mean duration of 84 months. Although the survival rate did not differ among the three TNF inhibitors in the AS patients, the etanercept group had a lower discontinuation rate than the infliximab group in the RA patients. In addition, RA patients who received corticosteroids in combination with TNF inhibitors were more likely to discontinue their TNF inhibitors. The independent predictors of drug discontinuation in AS patients were male gender and complete ankylosis on radiographs of the sacroiliac joint. Our results provide further evidence that real-life treatment outcomes of RA and AS patients may be different from those observed in randomized clinical trials.
Adult
;
Aged
;
Antibodies, Monoclonal/therapeutic use
;
Antibodies, Monoclonal, Humanized/therapeutic use
;
Antirheumatic Agents/*therapeutic use
;
Arthritis, Rheumatoid/*drug therapy/mortality
;
Cohort Studies
;
Female
;
Follow-Up Studies
;
Humans
;
Immunoglobulin G/therapeutic use
;
Male
;
Middle Aged
;
Proportional Hazards Models
;
Receptors, Tumor Necrosis Factor/therapeutic use
;
Sex Factors
;
Spondylitis, Ankylosing/*drug therapy/mortality/radiography
;
Tertiary Care Centers
;
Treatment Refusal
;
Tumor Necrosis Factors/*antagonists & inhibitors/metabolism
8.A Case of Acute Inflammatory Demyelinating Polyradiculoneuropathy in a Patient with Systemic Lupus Erythematosus.
Jeong Won LEE ; Ji Hyoun KANG ; Hyoung Ju HONG ; Sun Mi JU ; Kyung Eun LEE ; Lihui WEN ; Dong Jin PARK ; Tae Jong KIM ; Yong Wook PARK ; Shin Seok LEE
Journal of Rheumatic Diseases 2014;21(3):143-146
Neuropsychiatric manifestations in patients with systemic lupus erythematosus are fairly common, with a prevalence of 37~95%. Among 19 neuropsychiatric manifestations, acute inflammatory demyelinating polyradiculoneuropathy (AIDP) is quite rare, and is characterized by progressive, symmetric muscle weakness accompanied by absent or depressed deep tendon reflexes. Generally, plasma exchange and intravenous immunoglobulin are the main treatment modalities. Here, we report a case of AIDP in a 29-year-old SLE patient, who was fully recovered with a treatment of high-dose glucocorticoid and immunosuppressive agents. Ours case suggests that AIDP should be treated differently in SLE patients to avoid disastrous results.
Adult
;
Central Nervous System
;
Guillain-Barre Syndrome*
;
Humans
;
Immunoglobulins
;
Immunosuppressive Agents
;
Lupus Erythematosus, Systemic*
;
Muscle Weakness
;
Plasma Exchange
;
Polyradiculoneuropathy
;
Prevalence
;
Reflex, Stretch
9.A Case of Eosinophilic Polymyositis Treated with Immunosuppressants.
Jung Ho CHOI ; Ji Hyoun KANG ; Lihui WEN ; Jeong Won LEE ; Kyung Eun LEE ; Dong Jin PARK ; Yong Wook PARK ; Tae Jong KIM ; Shin Seok LEE
Journal of Rheumatic Diseases 2015;22(5):308-312
Eosinophilic polymyositis is a rare form of inflammatory muscle disease associated with peripheral blood and/or tissue eosinophilia. Most patients respond to glucocorticoids, however some show poor prognosis, leading to mortality. A 28-year-old female was admitted to our hospital because of myalgia and motor weakness of the upper and lower extremities. Laboratory findings showed significantly elevated levels of muscle enzymes and inflammatory lesions in both thigh muscles were demonstrated on magnetic resonance imaging. A diagnosis of eosinophilic polymyositis was based on histological findings, which showed diffuse eosinophilic infiltration into perivascular spaces in the endomysium and perimysium, and necrosis of myofibers. High-dose methylprednisolone treatment improved the clinical symptoms and muscle enzymes. However, on tapering the glucocorticoid dose, clinical and laboratory findings were exacerbated. After the addition of methotrexate and azathioprine, the symptoms and muscle enzymes recovered without relapse. Here, we report on a case of eosinophilic polymyositis, which responded to immunosuppressants.
Adult
;
Azathioprine
;
Diagnosis
;
Eosinophilia
;
Eosinophils*
;
Female
;
Glucocorticoids
;
Humans
;
Immunosuppressive Agents*
;
Lower Extremity
;
Magnetic Resonance Imaging
;
Methotrexate
;
Methylprednisolone
;
Mortality
;
Muscles
;
Myalgia
;
Myositis
;
Necrosis
;
Polymyositis*
;
Prognosis
;
Recurrence
;
Thigh
10.Application of telephone follow-up on the initial use of insulin glargine in patients with extended care
Junxiang GAO ; Shuo KANG ; Lijuan WANG ; Lihui ZHANG ; Limei GUO ; Xing ZHANG ; Yixuan WANG
Chinese Journal of Modern Nursing 2015;(36):4385-4387
Objective To evaluate the effects of the telephone follow-up on blood glucose and treatment compliance among patients with the initial use of insulin glargine. Methods A total of 100 inpatients with the initial use of insulin glargine were randomly assigned to a control group and an observation group according to the random number table method, with 50 cases each. The patients of control group received routine discharge guidance, while the patients of observation group received 5 times telephone follow-up leading by doctors and nurses in three months. Patients in both groups were followed up 3 months, and their fasting blood glucose, glycated hemoglobin ( HbA1c), and treatment compliance were measured before and 3 months after the intervention. Results There was no statistically significant difference in fasting blood glucose and values of HbA1c between two groups before the intervention (P >0. 05). The fasting blood glucose in the observation group was lower than that of the control group after 3 months intervention, and the Values of HbA1c in the observation group was lower than that of the control group after intervention (P<0. 05); the behavior of diet, blood glucose monitoring, insulin treatment compliance in the observation group better than those in the control group (P<0. 05). The Compliance of exercise behavior in the observation group had no significant difference with that of the control group ( P > 0. 05 ). Conclusions Telephone follow-up can improve patient′s compliance, which is favorable for glycemic control after discharge in patients with the initial use insulin glargine.